Product Information
Registration Status: ActiveSIN08206P
SPORANOX CAPSULE 100mg is approved to be sold in Singapore with effective from 1995-10-06. It is marketed by JOHNSON & JOHNSON PTE LTD, with the registration number of SIN08206P.
This product contains Itraconazole 100mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by JANSSEN CILAG S P A in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]
Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Mechanism of Action
Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
Pharmacokinetics
- Absorption
- The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.
- Distribution
- * 796 ± 185 L
- Metabolism
- Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.
- Elimination
Clearance
* 381 +/- 95 mL/minute [IV administration]
Toxicity
No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.
Active Ingredient/Synonyms
Itraconazol | Itraconazole | Itraconazolum | Itrizole (tn) | Oriconazole | Sporanox (tn) | Itraconazole |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.